Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
about
Icotinib is an active treatment of non-small-cell lung cancer: a retrospective studyNetwork meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutationsFirst-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancerThird-line systemic treatment for non-small cell lung cancerFirst-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerCancer pharmacogenomics: strategies and challengesTrials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and FutureMolecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancersFirst-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerCrizotinib: from discovery to accelerated development to front-line treatmentThe role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancerNot all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyIntrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerAfatinib in Non-Small Cell Lung CancerA new needle on the block: EchoTip ProCore endobronchial ultrasound needlePulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled TrialsOral targeted therapy for cancerRole of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present eraNovel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapiesTreatment of advanced squamous cell carcinoma of the lung: a reviewChina experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)Clinical development of nintedanib for advanced non-small-cell lung cancerDacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future HoldsIdentifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancerProgress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancerNovel targeted agents for the treatment of lung cancer in ChinaThe Evolution of Therapies in Non-Small Cell Lung CancerThe Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic AnalysisA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesAnalysis of different HER-2 mutations in breast cancer progression and drug resistanceExpert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UKTargeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughChina Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)Using large-scale genomics data to identify driver mutations in lung cancer: methods and challengesThe role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agentsThe Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic TestingCombating acquired resistance to tyrosine kinase inhibitors in lung cancer
P2860
Q21132047-2BF619A7-28FF-4B32-A0CE-65DCDE93ECA0Q21132357-7F897B45-5E09-4651-B815-C59445F1E1DFQ21198843-52670C2D-9286-4E73-ACF0-BACF449DA9CCQ24194090-2642B253-3A0D-4FF5-AB94-76FB171052D6Q24201207-15A79134-60BD-43C0-A087-954D0985C6B2Q24289309-8C440138-2FF6-45D6-9305-7FD735B338DBQ24564024-75114EE2-0080-49D1-BEBE-FF716062937DQ24611043-F6308988-B3E5-4085-BF9E-27EC194EC19EQ26471909-E4AF83AE-23C0-4F4E-871B-80EF4FF93430Q26738385-942A891D-E810-44A7-8474-0DBCD910C652Q26740529-46FCCA36-1476-4D55-8DCB-41C842C631D0Q26744284-A0B29FF6-F8EA-4947-8D7E-3FFFDDB3BC00Q26744339-3E32F3F8-9B94-413A-B41D-F843E936108CQ26745427-58750CA4-4A54-4C81-8E76-ADE3B458059BQ26749005-A8D90BD9-9D61-4059-9B58-F7048D2C1531Q26751329-01CC8D4A-10F6-4B76-B312-72591730C97EQ26768125-DA6BC710-B39B-45CC-AD92-380D264A40B7Q26773240-69C3C7B8-82BC-49D2-9168-3FE7686E930BQ26774726-E31E0D51-ADA2-415E-BC38-4329D79D3137Q26775388-89EB4E14-99B6-4936-90BC-94CD3BF811B0Q26775392-7CC00094-74FD-499F-BA81-253D0A138A3CQ26775603-AE2497A6-1DEB-4789-B8F2-5D9A7A26DFAAQ26775677-CA5E9B8C-5C17-4700-9486-182CEAC11390Q26775822-2534CA24-535D-41AC-94E6-06C1CDE1415EQ26778318-40B2C0CE-A119-44D0-AA33-F7BF6B0B34F9Q26781662-DEB0A642-A5E3-407D-AE9F-AB5B6979EB1DQ26781810-270EE742-AF98-4E21-BDA5-F750615A0244Q26784298-79DDEE9C-1BF7-4EA9-8D0E-4AA9120B7610Q26786580-D26A4905-A4BB-4D61-8B83-C467CDC67B4DQ26786932-3EFFC3FE-28A1-4608-9D49-5CE36113445EQ26797117-D1AD2E66-52A5-4B30-8BCF-C680784C373DQ26797297-C2E8670F-964E-48E2-897D-36C420BD6F7FQ26797471-84FC9D21-D5BC-44DE-8F96-2DB3D05AA481Q26799390-A245743D-2B8B-44E0-B9ED-E62C728CCEE8Q26799467-F759F83F-F2E5-4000-9BCC-9C194BCADDC8Q26800148-3D33D245-57FA-4457-BD8E-96E9E8CB3E56Q26800833-6299E9A9-7B35-41C2-9DC4-FEE9B1C68203Q26823903-940BF3C9-8FD2-4186-9C2D-600D84C83E15Q26824315-05DD6834-9508-48E0-8442-08FC6F342016Q26824877-342E407F-EA7B-4AEA-8710-9331CF9F6FFF
P2860
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Gefitinib versus cisplatin plu ...... abel, randomised phase 3 trial
@ast
Gefitinib versus cisplatin plu ...... abel, randomised phase 3 trial
@en
type
label
Gefitinib versus cisplatin plu ...... abel, randomised phase 3 trial
@ast
Gefitinib versus cisplatin plu ...... abel, randomised phase 3 trial
@en
prefLabel
Gefitinib versus cisplatin plu ...... abel, randomised phase 3 trial
@ast
Gefitinib versus cisplatin plu ...... abel, randomised phase 3 trial
@en
P2093
P3181
P1433
P1476
Gefitinib versus cisplatin plu ...... abel, randomised phase 3 trial
@en
P2093
Hirashima T
Katakami N
Mitsudomi T
Nakagawa K
P3181
P356
10.1016/S1470-2045(09)70364-X
P407
P577
2010-02-01T00:00:00Z